Works matching IS 14440903 AND DT 2016 AND VI 46 AND IP 9


Results: 29
    1
    2
    3
    4
    5
    6
    7

    Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.

    Published in:
    Internal Medicine Journal, 2016, v. 46, n. 9, p. 1054, doi. 10.1111/imj.13166
    By:
    • Gibson, P. G.;
    • Reddel, H.;
    • McDonald, V. M.;
    • Marks, G.;
    • Jenkins, C.;
    • Gillman, A.;
    • Upham, J.;
    • Sutherland, M.;
    • Rimmer, J.;
    • Thien, F.;
    • Katsoulotos, G. P.;
    • Cook, M.;
    • Yang, I.;
    • Katelaris, C.;
    • Bowler, S.;
    • Langton, D.;
    • Robinson, P.;
    • Wright, C.;
    • Yozghatlian, V.;
    • Burgess, S.
    Publication type:
    Article
    8
    9
    10

    The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.

    Published in:
    Internal Medicine Journal, 2016, v. 46, n. 9, p. 1075, doi. 10.1111/imj.13173
    By:
    • Stamp, L. K.;
    • Haslett, J.;
    • Frampton, C.;
    • White, D.;
    • Gardner, D.;
    • Stebbings, S.;
    • Taylor, G.;
    • Grainger, R.;
    • Kumar, R.;
    • Kumar, S.;
    • Kain, T.;
    • Porter, D.;
    • Corkill, M.;
    • Cathro, A.;
    • Metcalfe, S.;
    • Wyeth, J.;
    • Dalbeth, N.
    Publication type:
    Article
    11
    12
    13
    14
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Issue Information - JEB.

    Published in:
    Internal Medicine Journal, 2016, v. 46, n. 9, p. 997, doi. 10.1111/imj.13225
    Publication type:
    Article
    26
    27
    28

    Author reply.

    Published in:
    Internal Medicine Journal, 2016, v. 46, n. 9, p. 1118, doi. 10.1111/imj.13189
    By:
    • Nagata, M.
    Publication type:
    Article
    29